# Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

> **NCT06873100** · PHASE1,PHASE2 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Relapsing Polychondritis

## Interventions

- **DRUG:** Upadacitinib
- **DRUG:** corticosteroids and immunosuppressants

## Key facts

- **NCT ID:** NCT06873100
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06873100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06873100, "Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06873100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*